Background {#Sec1}
==========

The incidence of infections with methicillin resistant *Staphylococcus aureus* (MRSA) is thought to be on the decline in Germany. This is corroborated by data from the national mandatory reporting system \[[@CR1]\], from a hospital surveillance system \[[@CR2]\], from surveys \[[@CR3]\] and from analysis of data submitted to the European Antimicrobial Resistance Surveillance Network \[[@CR4]\]. However, these analyses rely on invasive samples or on samples from hospitals only. Little is known about trends in the incidence of non-invasive MRSA infections and about that of MRSA infections in outpatient settings \[[@CR5], [@CR6]\].

The MRSA epidemic in Germany and Europe is thought to be mainly health-care associated based on the age distribution of cases \[[@CR1]\] and molecular analysis of the isolates \[[@CR7]\]. However, there are regions with a high density of swine farming, where livestock-associated (LA) MRSA makes up a considerable proportion of MRSA infections seen in hospitals. For example, one study found 8% of all MRSA blood cultures to be associated with LA-MRSA \[[@CR8]\]. Community-associated (CA) MRSA is regularly found throughout Germany, even though it remains relatively rare \[[@CR9]\]. Trends for LA- and CA-MRSA are not well reflected by the above mentioned surveillance systems, since this would require a more thorough data collection, ideally including the molecular characterization of isolates.

The Antimicrobial Resistance Surveillance Network (ARS) collects routine data on antibiotic resistance testing from voluntarily participating laboratories \[[@CR10]\]. In contrast to other surveillance systems, ARS includes data on antibiotic susceptibility testing of *S. aureus* isolates from a number of sample types and settings including non-invasive samples and outpatient settings. It also includes data on co-resistance to other antibiotics for a large number of MRSA isolates. To complement recent analysis of declining MRSA infections in invasive samples and in hospitals \[[@CR1]--[@CR4]\] and to extend previous analysis from ARS \[[@CR5], [@CR11]\], we investigated whether declining trends of MRSA may be seen for all clinical settings, including outpatient settings, and for all sample types, including non-invasive samples. We further investigated whether or not there are changes in MRSA's co-resistance profiles.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Among all data submitted to ARS, we selected facilities who submitted data for the entire study period from 2010 to 2015. We excluded screening samples (i.e. those marked as screening samples, those collected from swabs from the nose/throat and anal swabs) as well as those from unspecified sample types. We selected the first isolate of *S. aureus* per patient and year that had a valid test result for oxacillin (or to a comparable antibiotic, such as cefoxitin). We compared the proportion of *S. aureus* isolates that are resistant to oxacillin by year and stratified the analysis by type of care or by sample type. Among oxacillin resistant isolates we compared the proportion that were non-susceptible to other selected antibiotics by year.

Statistical analysis {#Sec4}
--------------------

We grouped sample types into 7 groups: In addition to blood culture and urine, we included swabs from lesions and abscesses in one group ("lesions"). We grouped together swabs from eyes, ears, tonsils/throat, tongue, urogenital tract, those collected during surgery, as well as other and non-specified swabs ("swabs"). We also grouped together biopsies from tissues, liquor, abscesses, ascites, joints, pleural cavity, other and non-specified punctures ("biopsies"). We grouped together bronchial lavage, bronchial secretions, sputum, tracheal secretion and other respiratory samples ("respiratory sample"). The remaining samples were dialysate, ejaculate, skin, hairs, nails, catheters, faeces and unspecified samples ("other samples"). For the analysis of co-resistance, we used non-susceptibility as the outcome, grouping together resistant and intermediate test results. Due to cross-resistance between tetracycline and doxycycline, we grouped these two antibiotics together as the group of tetracyclines. In the analysis stratified by federal states, we excluded samples from several states with data for only few patients.

For univariate analysis we used chi-square tests unless the expected cell count was below 5, in which case we used Fisher's exact test. We corrected for multiple testing using Bonferroni correction (i.e. dividing the p-value of 0.05 by the number of conducted tests \[i.e. 27 for temporal differences in the frequency of oxacillin resistance; 6 for factors associated with non-susceptibility to tetracyclines\]).

Results {#Sec5}
=======

Characteristics of included isolates {#Sec6}
------------------------------------

The analysis included 148,561 isolates from 6 laboratories representing 1,855 different outpatient clinics and 105 hospitals. Even though statistically significant, changes over the years were generally small for the distribution of the samples by category of age, sex, federal state of the sending facility, sample type, type of care or clinical speciality (Table [1](#Tab1){ref-type="table"}).Table 1Number and characteristics of *S. aureus* isolates included in the analysis, ARS, Germany 2010-20152010 \[n (%)\]2011 \[n (%)\]2012 \[n (%)\]2013 \[n (%)\]2014 \[n (%)\]2015 \[n (%)\]*p*-valueN24 66725 12525 99525 54425 02822 202Age \[years\]\<0.001 0--92 170 (9)2 163 (9)2 210 (9)1 969 (8)1 673 (7)1 524 (7) 10--191 321 (5)1 335 (5)1 461 (6)1 319 (5)1 199 (5)1 105 (5) 20--291 440 (6)1 551 (6)1 522 (6)1 531 (6)1 501 (6)1 333 (6) 30--391 349 (5)1 394 (6)1 378 (5)1 369 (5)1 269 (5)1 203 (5) 40--492 049 (8)2 175 (9)2 144 (8)2 043 (8)1 864 (7)1 687 (8) 50--592 721 (11)2 736 (11)2 945 (11)2 892 (11)2 878 (11)2 588 (12) 60--693 446 (14)3 497 (14)3 493 (13)3 611 (14)3 569 (14)3 150 (14) 70--795 439 (22)5 491 (22)5 714 (22)5 771 (23)5 657 (23)4 830 (22) 80+4 732 (19)4 783 (19)5 128 (20)5 039 (20)5 418 (22)4 782 (22)Sex\<0.001 Women8 764 (36)9 159 (36)9 728 (37)10 640 (42)10 144 (41)9 204 (41) Men10 151 (41)10 412 (41)11 215 (43)11 995 (47)11 646 (47)10 242 (46) Not specified5 752 (23)5 554 (22)5 052 (19)2 909 (11)3 238 (13)2 756 (12)Federal state\<0.001 Baden-Württemberg4 634 (19)4 844 (19)4 709 (18)4 882 (19)2 839 (11)2 886 (13) Bavaria609 (2)565 (2)635 (2)688 (3)714 (3)784 (4) Berlin1 678 (7)1 885 (8)1 889 (7)2 029 (8)2 108 (8)2 218 (10) Hesse848 (3)832 (3)1 045 (4)1 125 (4)1 203 (5)1 283 (6) North Rhine-Westphalia11 778 (48)11 838 (48)12 465 (48)12 758 (50)13 809 (56)10 652 (49) Rhineland Palatinate2 387 (10)2 322 (9)2 351 (9)2 301 (9)2 512 (10)2 397 (11) Schleswig-Holstein2 511 (10)2 598 (10)2 659 (10)1 524 (6)1 622 (7)1 728 (8)Sample type\<0.001 Swabs9 352 (38)9 383 (37)9 720 (37)8 819 (35)8 669 (35)8 077 (36) Blood cultures1 109 (4)1 172 (5)1 263 (5)1 262 (5)1 250 (5)1 093 (5) Biopsies469 (2)505 (2)528 (2)560 (2)459 (2)410 (2) Respiratory samples2 537 (10)2 523 (10)2 624 (10)2 687 (11)2 508 (10)2 345 (11) Urine2 494 (10)2 508 (10)2 569 (10)2 456 (10)2 508 (10)1 973 (9) Lesions8 118 (33)8 427 (34)8 701 (33)9 098 (36)9 109 (36)7 795 (35) Other588 (2)607 (2)590 (2)662 (3)525 (2)509 (2)Type of care0.016 Outpatient care10 846 (44)11 537 (46)11 588 (45)11 506 (46)10 811 (44)10 209 (46) ICU1 798 (7)1 857 (7)2 002 (8)1 875 (7)1 716 (7)1 620 (7) Normal hospital ward11 920 (49)11 600 (46)12 104 (47)11 793 (47)12 001 (49)10 223 (46)Clinical specialty\<0.001 Surgery and related5 208 (21)5 040 (20)5 226 (20)5 047 (20)4 832 (19)3 843 (17) Internal/conservative12 160 (49)12 339 (49)12 652 (49)12 620 (49)12 355 (49)10 949 (49) Other7 299 (30)7 746 (31)8 117 (31)7 877 (31)7 841 (31)7 410 (33)ICU = intensive care unit. The numbers may not tally to the total due to missing data or due to a low frequency of entries, which do not fit the categories shown (i.e. for type of care and for federal state)

Oxacillin resistance {#Sec7}
--------------------

The overall frequency of oxacillin resistance decreased continuously from 16% (*n* = 4,058) in 2010, to 15% (*n* = 3,853) in 2011, 14% (*n* = 3,675) in 2012, 12% (*n* = 3,129) in 2013, 12% (*n* = 2,974) in 2014 to 10% (*n* = 2,223) in 2015 (*p* \< =0.001).

There were significant declines in the proportion of MRSA among all *S. aureus* isolates for all types of care (Fig. [1](#Fig1){ref-type="fig"}, upper panel). As expected, the proportion of MRSA was generally lower in the outpatient setting than in hospitals. However, the relative decline was markedly lower in the outpatient setting than in the hospital setting (12 to 8% between 2010 and 2015 versus 26 to 11% in ICU and 19 to 12% in non-ICU hospital wards), closing the gap between these two types of care.Fig. 1MRSA among *S. aureus* isolates by type of care or sample type, ARS, Germany, 2010--2015. Legend: The asterisk marks significant changes (*p* \< 0.0019)

There was a strong decline in the proportion of MRSA among *S. aureus* isolates for all sample types except for biopsies and other samples, for which the p-value did not reach statistical significance after adjustment for multiple testing (i.e. *p* \< 0.0019) (Fig. [1](#Fig1){ref-type="fig"}, lower panel).

Non-susceptibility of MRSA to other antibiotics {#Sec8}
-----------------------------------------------

Figure [2](#Fig2){ref-type="fig"} depicts the non-susceptibility of MRSA isolates to other selected antibiotics per calendar year. At least three different patterns can be identified: Firstly, antibiotics with high (\>30%) but decreasing levels of non-susceptibility (i.e. tobramycin, ciprofloxacin, moxifloxacin, clindamycin, erythromycin); secondly, antibiotics with low (≤5%) and decreasing or stable levels of non-susceptibility (i.e. teicoplanin, vancomycin, daptomycin, fosfomycin, fusidic acid, linezolid, mupirocin, rifampicin, cotrimoxazole and tigecyline); thirdly, two antibiotics or groups of antibiotics with relatively low levels (\<10%) but increasing levels of non-susceptibility (i.e. gentamicin and tetracyclines). The absolute numbers of isolates with non-susceptibility to gentamicin (2010 to 2015: *n* = 135, 145, 164, 104, 114 and 130) or to tetracyclines (2010 to 2015: *n* = 225, 293, 262, 233, 282 and 203) remained relatively stable over the years, due to the decline in the overall number of MRSA isolates.Fig. 2Non-susceptibility of MRSA isolates to selected antibiotics, ARS, Germany, 2010--2015. Legend: The table shows the number of tested isolates. The asterisk marks significant changes (*p* \< 0.0019)

Since non-susceptibility to tetracyclines has been found to be associated with LA-MRSA in several studies \[[@CR12]--[@CR18]\], we analysed the associated factors. We found non-susceptibility to tetracyclines to be associated with young age (Table [2](#Tab2){ref-type="table"}). While there was no difference between the two sexes (*p* = 0.13), non-susceptibility was higher if for technical reasons the sex had not been specified. There were also significant differences between German federal states, however with no clear pattern. Non-susceptibility was relatively high among isolates from swabs, biopsies, lesions and other samples, but lower in isolates from blood culture. As expected it was higher in samples from outpatient settings than from hospitals (*p* = 0.004 for outpatient versus both hospital settings). Non-susceptibility to tetracyclines was more frequent among isolates from surgery than in those from other clinical specialities.Table 2Non-susceptibility of MRSA isolates to tetracyclines, Antimicrobial Resistance Surveillance Network -- ARS, Germany, 2010--2015N MRSA isolates tested for tetracycline resistancen (%) non-susceptible to tetracyclines*p*-valueN19 7211 498 (8)Age \[years\]\<0.001 0--941479 (19) 10--1921645 (21) 20--2936764 (17) 30--3943675 (17) 40--49936107 (11) 50--591 883180 (10) 60--693 219252 (8) 70--796 093357 (6) 80+6 157339 (6)Sex\<0.001 Women6 449428 (7) Men8 736635 (7) Unspecified4 536435 (10)Federal state\<0.001 Baden-Württemberg2 544134 (5) Bavaria33647 (14) Berlin1 24884 (7) Hesse66440 (6) North Rhine-Westphalia11 445942 (8) Rhineland Palatinate1 79086 (5) Schleswig-Holstein1 534159 (10)Sample type\<0.001 Swabs (other than from lesions)6 059498 (8) Blood culture92643 (5) Biopsies30232 (11) Respiratory sample2 538183 (7) Urine3 006166 (6) Lesion6 455541 (8) Other43535 (8)Type of care0.016 Outpatient care6 668553 (8) Intensive care unit2 048142 (7) Normal hospital ward10 780776 (7)Clinical specialty0.001 Surgery3 943348 (9) Internal/conservative10 645748 (7) Other5 133402 (8)The numbers may not tally to the total due to missing data or due to a low frequency of entries, which do not fit the categories shown (i.e. for type of care and for federal state)

Discussion {#Sec9}
==========

The proportion of MRSA among *S. aureus* isolates from non-invasive samples and from those in the outpatient setting decreased significantly between 2010 and 2015. Similarly, non-susceptibility of MRSA isolates to several other antibiotics decreased between 2010 and 2015, while that to gentamicin and to tetracyclines increased. Non-susceptibility to last line antibiotics, including tigecycline, linezolid, vancomycin and teicoplanin, fortunately remained rare.

Our data are also consistent with previous analyses that have indicated declines in MRSA in the hospital setting and for invasive infections \[[@CR1]--[@CR3]\], with the previous analysis of ARS data from outpatient setting \[[@CR5]\] and indirectly also with data from the national reference laboratory that suggest low levels of LA- and CA-MRSA in Germany \[[@CR6], [@CR9]\]. Therefore, they indicate a general decline in MRSA-infection in Germany in all settings and for all sample types.

A decline in MRSA infections in Germany may have various reasons as discussed previously \[[@CR1]\]. It is likely that control mechanisms implemented in Germany contribute to this success. However, additional factors, such as normally occurring changes in the circulating strains cannot be excluded \[[@CR19]\].

Of note is the relative increase in the non-susceptibility of MRSA isolates to tetracyclines. Non-susceptibility to tetracyclines had been found to be associated with LA-MRSA \[[@CR13]--[@CR18]\]. We found it to be associated with --among other factors - young age and samples from outpatient settings, which would be consistent with LA-MRSA. Since, however, non-susceptibility to tetracyclines also occurs independently of LA-MRSA \[[@CR12]\], we cannot with certainty attribute trends in non-susceptibility to tetracyclines to an increase in LA-MRSA. An increase in the proportion of LA-MRSA among all MRSA isolates would however be consistent with two previous studies that showed an increase of LA-MRSA between 2004/2005 and 2010/2011 \[[@CR20]\] as well as stable levels of LA-MRSA in recent years \[[@CR12]\] (while other forms of MRSA have declined). The relevance of LA-MRSA in Germany therefore warrants further investigations.

The proportion of MRSA among *S. aureus* isolates is an imperfect indicator for the incidence of MRSA infections, because it may be influenced by the frequency of diagnostic sampling \[[@CR21]\], the time of sample collection, changes in treatment practice and because it does not include a defined population as denominator. As with all routine data from voluntary sources, an additional limitation of this analysis is the possibility of a changing study base and a potential non-representativeness of the data for all of Germany. Since, however, the baseline characteristics (Table [1](#Tab1){ref-type="table"}) remained relatively stable over the time period included in the study and since the results for the blood cultures showed consistent trends with data from other sources \[[@CR1], [@CR2]\], we believe our results to be indicative for trends in the incidence of MRSA infections in Germany.

Conclusion {#Sec10}
==========

The presented data from ARS corroborate a general decline of MRSA infections in Germany including in the outpatient setting and in non-invasive samples. The co-resistance profiles changed markedly and should be further analysed using genotyping studies.
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:   Methicillin resistant *Staphylococcus aureus*
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